Jennerex Presents Positive Clinical Data From Phase II Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients

Jennerex presented Phase II clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma.
Yahoo! Finance